disopyramide

CV: HF, arrhythmias, dyspnea, edema, heart block, hypotension

EENT: dry eyes, blurred vision, dry throat

Endo: hypoglycemia

GI: constipation, dry mouth, abdominal pain, flatulence, nausea

GU: urinary hesitancy, urinary retention

Neuro: fatigue, dizziness, headache

Misc: impaired temperature regulation

Interactions ⬆ ⬇

Drug-drug:

May potentiate anticoagulant effect of warfarin.
Rifampin, phenobarbital, and phenytoin may ↓ levels and effectiveness.
Cimetidine orerythromycin may ↑ levels and risk of toxicity.
May have additive toxic cardiac effects when used with other antiarrhythmics (prolonged conduction and ↓ cardiac output), especially verapamil—avoid using disopyramide for 48 hr before or 24 hr after.
Anticholinergic side effects may be additive with other drugs having anticholinergic properties, including antihistamines and TCAs.
↑risk of arrhythmias with pimozide.

Drug-Natural Products:

↑anticholinergic effects with angel's trumpet, jimson weed, and scopolia.

Route/Dosage ⬆ ⬇

PO (Adults >50 kg): 150 mg every 6 hr (as immediate-release capsules) or 300 mg every 12 hr (as CR dosage form; not to exceed 800 mg/day).
PO (Adults <50 kg or Patients with Poor Left Ventricular Function): 100 mg every 6–8 hr (as immediate-release capsules) or 200 mg every 12 hr (as CR dosage form).
PO (Children 12–18 yr): 6–15 mg/kg daily, in divided doses every 6 hr.
PO (Children 4–12 yr): 10–15 mg/kg daily in divided doses every 6 hr.
PO (Children 1–4 yr): 10–20 mg/kg daily in divided doses every 6 hr.
PO (Children <1 yr): 10–30 mg/kg daily in divided doses every 6 hr.

Renal Impairment

PO (Adults ): CCr >40 mL/min or patients with hepatic impairment: 100 mg every 6 hr; CCr 30–40 mL/min: 100 mg every 8 hr; CCr 15–30 mL/min: 100 mg every 12 hr; CCr <15 mL/min: 100 mg every 24 hr as immediate-release dosage form.

Availability ⬆ ⬇

(Generic available)

Capsules: 100 mg; 150 mg
Extended-release capsules: 100 mg; 150 mg

Assessment ⬆ ⬇

Monitor BP, pulse, and ECG before and routinely during therapy. Check pulse before administering medication; hold and notify health care professional if <60 or >120 bpm or if changes in rhythm.
Monitor intake and output ratios and daily weight; assess for edema and urinary retention daily.
Assess patient for signs of heart failure (peripheral edema, rales/crackles, dyspnea, weight gain, jugular venous distention). Notify health care professional if these occur.

Lab Test Considerations:

Renal and hepatic functions and serum potassium levels should be evaluated periodically throughout therapy.
- May cause elevated serum BUN, cholesterol, and triglyceride levels.
- May cause decreased blood glucose concentrations.

Implementation ⬆ ⬇

Do not confuse disopyramide with desipramine.
When changing from quinidine sulfate to disopyramide, regular maintenance dose of disopyramide may be given 6–12 hr after last dose of quinidine sulfate.
- Extended-release form (CR formulations) is indicated for maintenance therapy only. When changing from regular form to extended-release forms, give the first dose of extended-release form 6 hr after the last regular dose.
PO: Administer medication on an empty stomach, 1 hr before or 2 hr after meals, around the clock, not 4 times/day to maintain therapeutic blood levels
- DNC: CR form must be swallowed whole; do not break open, crush, or chew.
- Pharmacist may prepare a suspension with 100-mg capsules and cherry syrup.

Patient/Family Teaching ⬆ ⬇

Advise patient to take medication around the clock, as directed. Do not discontinue medication without consulting health care professional. If a dose is missed, take as soon as remembered unless within 4 hr of next dose. Do not double doses.
Medication may cause dizziness. Caution patients to avoid driving or other activities requiring alertness until response to medication is known.
Instruct patient to change positions slowly to minimize orthostatic hypotension.
Advise patient that frequent mouth rinses, good oral hygiene, and sugarless gum or candy may help relieve dry mouth.
Caution patient to avoid extremes of temperature, because this medication may cause impairment of body temperature regulation. Patient should use sunscreen and protective clothing to prevent photosensitivity reactions.
Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult health care professional before taking other Rx, OTC, herbal products, or alcohol.
If constipation becomes a problem, advise patient that increasing bulk and fluids in the diet and exercising may minimize constipation.
Instruct patient to notify health care professional if dry mouth, difficult urination, constipation, or blurred vision persists.
Rep: May cause fetal harm. Advise females of reproductive potential to notify health care professional promptly if pregnancy is planned or suspected and to avoid breastfeeding during therapy.

Evaluation/Desired Outcomes ⬆ ⬇

Suppression of ventricular arrhythmias.

US Brand Names ⬆ ⬇

Canadian Brand Names ⬆ ⬇

Code ⬆

NDC Code

0025- G.D. Searle LLC Division of Pfizer Inc
- 0025-2732- Norpace CR
  - 0025-2732-31- 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0025-2732-31)

0025- G.D. Searle LLC Division of Pfizer Inc
- 0025-2732- Norpace CR
  - 0025-2732-34- 100 CAPSULE, EXTENDED RELEASE in 1 BOX, UNIT-DOSE (0025-2732-34)

0025- G.D. Searle LLC Division of Pfizer Inc
- 0025-2742- Norpace CR
  - 0025-2742-31- 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0025-2742-31)

0025- G.D. Searle LLC Division of Pfizer Inc
- 0025-2742- Norpace CR
  - 0025-2742-34- 100 CAPSULE, EXTENDED RELEASE in 1 BOX, UNIT-DOSE (0025-2742-34)

0025- G.D. Searle LLC Division of Pfizer Inc
- 0025-2752- Norpace
  - 0025-2752-31- 100 CAPSULE, GELATIN COATED in 1 BOTTLE (0025-2752-31)

0025- G.D. Searle LLC Division of Pfizer Inc
- 0025-2752- Norpace
  - 0025-2752-52- 1000 CAPSULE, GELATIN COATED in 1 BOTTLE (0025-2752-52)

0025- G.D. Searle LLC Division of Pfizer Inc
- 0025-2762- Norpace
  - 0025-2762-31- 100 CAPSULE, GELATIN COATED in 1 BOTTLE (0025-2762-31)

0025- G.D. Searle LLC Division of Pfizer Inc
- 0025-2762- Norpace
  - 0025-2762-52- 1000 CAPSULE, GELATIN COATED in 1 BOTTLE (0025-2762-52)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-3127- Disopyramide Phosphate
  - 0093-3127-01- 100 CAPSULE in 1 BOTTLE (0093-3127-01)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-3129- Disopyramide Phosphate
  - 0093-3129-01- 100 CAPSULE in 1 BOTTLE (0093-3129-01)

42291- AvKARE, Inc.
- 42291-234- Disopyramide Phosphate
  - 42291-234-01- 100 CAPSULE in 1 BOTTLE (42291-234-01)

42291- AvKARE, Inc.
- 42291-235- Disopyramide Phosphate
  - 42291-235-01- 100 CAPSULE in 1 BOTTLE (42291-235-01)

51407- Golden State Medical Supply Inc.
- 51407-131- DISOPYRAMIDE PHOSPHATE
  - 51407-131-01- 100 CAPSULE in 1 BOTTLE (51407-131-01)

51407- Golden State Medical Supply Inc.
- 51407-132- DISOPYRAMIDE PHOSPHATE
  - 51407-132-01- 100 CAPSULE in 1 BOTTLE (51407-132-01)

51862- Mayne Pharma Inc.
- 51862-093- Disopyramide Phosphate
  - 51862-093-01- 100 CAPSULE in 1 BOTTLE, PLASTIC (51862-093-01)

51862- Mayne Pharma Inc.
- 51862-094- Disopyramide Phosphate
  - 51862-094-01- 100 CAPSULE in 1 BOTTLE, PLASTIC (51862-094-01)

51862- Mayne Pharma Inc.
- 51862-095- DISOPYRAMIDE PHOSPHATE
  - 51862-095-01- 100 CAPSULE in 1 BOTTLE (51862-095-01)

51862- Mayne Pharma Inc.
- 51862-096- DISOPYRAMIDE PHOSPHATE
  - 51862-096-01- 100 CAPSULE in 1 BOTTLE (51862-096-01)

59762- Greenstone LLC
- 59762-0386- Disopyramide Phosphate
  - 59762-0386-1- 100 CAPSULE, GELATIN COATED in 1 BOTTLE (59762-0386-1)

59762- Greenstone LLC
- 59762-0400- Disopyramide Phosphate
  - 59762-0400-1- 100 CAPSULE, GELATIN COATED in 1 BOTTLE (59762-0400-1)

60429- GSMS, Incorporated
- 60429-984- Disopyramide Phosphate
  - 60429-984-01- 100 CAPSULE in 1 BOTTLE, PLASTIC (60429-984-01)

60429- GSMS, Incorporated
- 60429-985- Disopyramide Phosphate
  - 60429-985-01- 100 CAPSULE in 1 BOTTLE, PLASTIC (60429-985-01)

ROUTE	ONSET	PEAK	DURATION
PO	0.5–3.5 hr	2.5 hr	1.5–8.5 hr
PO-CR	0.5–3.5 hr	4.9 hr	12 hr

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇

Time/Action Profile ⬆ ⬇

Contraind./Precautions ⬆ ⬇

Adv. Reactions/Side Effects ⬆ ⬇